Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 19/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.79 |
| ▸ | CCR4 | P51679 | 4/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.77 |
| ▸ | CCR5 | P51681 | 2/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4903092 | 0.90 | CCR2 (0.80) | CCR2CYP3A4CYP2C9CYP2C19CCR4 | |
| SCHEMBL14006397 | 0.89 | CCR2 (0.82) | CCR2CYP3A4CYP2C9CYP2C19CCR4 | |
| SCHEMBL4910021 | 0.89 | CCR2 (0.87) | CCR2CYP3A4CYP2C9CYP2C19CCR4 | |
| SCHEMBL4909619 | 0.89 | CCR2 (1.00) | CCR2CYP3A4CYP2C9CYP2C19CCR4 | |
| SCHEMBL4908265 | 0.87 | CCR2 (1.00) | CCR2CYP3A4CYP2C9CYP2C19CCR4 | |
| SCHEMBL4914005 | 0.87 | CCR2 (0.74) | CCR2CYP3A4CYP2C9CYP2C19CCR4 | |
| SCHEMBL4911238 | 0.86 | CCR2 (0.82) | CCR2CYP3A4CYP2C9CYP2C19CCR4 | |
| SCHEMBL4901927 | 0.85 | CCR2 (0.76) | CCR2CYP3A4CYP2C9CYP2C19CCR4 | |
| SCHEMBL4910707 | 0.85 | CCR2 (0.70) | CCR2CYP3A4CYP2C9CYP2C19CCR4 | |
| SCHEMBL14006346 | 0.84 | CCR2 (0.83) | CCR2CYP3A4CYP2C9CYP2C19CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293720-A1 | Pyridinyl Sulfonamide Modulators of Chemokine Receptors | GLAXO GROUP LIMITED (GB) | 2008-11-27 | — | — | US | disclosed |
| US-20080293720-A1 | Pyridinyl Sulfonamide Modulators of Chemokine Receptors | GLAXO GROUP LIMITED (GB) | 2008-11-27 | — | — | US | disclosed |
| US-20080293720-A1 | Pyridinyl Sulfonamide Modulators of Chemokine Receptors | GLAXO GROUP LIMITED (GB) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293720-A1 | Pyridinyl Sulfonamide Modulators of Chemokine Receptors | CCR2, CCR1, CCRL2 | CCR2 1/4885CYP3A4 1414/4885CYP2C9 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.